Search

Your search keyword '"Sebbane M"' showing total 4 results
Start Over Author "Sebbane M" Language undetermined
4 results on '"Sebbane M"'

1. Chronic use of inhaled corticosteroids in patients admitted for respiratory virus infections: a 6-year prospective multicenter study

Author

Luque-Paz, David, Tattevin, Pierre, Loubet, Paul, Bénézit, François, Thibault, Vincent, Lainé, Fabrice, Vanhems, Philippe, Amour, Selilah, Lina, Bruno, Duval, Xavier, L’honneur, Anne-Sophie, Fidouh, Nadhira, Vallejo, Christine, Alain, Sophie, Galtier, Florence, Foulongne, Vincent, Lagathu, Gisèle, Lenzi, Nezha, Lesieur, Zineb, Launay, Odile, Jouneau, Stéphane, Loulergue, P., Momcilovic, S., Mira, J., Marin, N., Charpentier, J., Regent, A., Kanaan, R., Dumas, F., Doumenc, B., Lachatre, M., Szwebel, T., Kansao, J., Costa, Y., Alexandra, J., Becheur, H., Belghalem, K., Bernard, J., Bleibtreu, A., Boisseau, M., Bories, R., Brugiere, O., Brunet, F., Burdet, C., Casalino, E., Caseris, M., Chansiaux, C., Chauchard, M., Chavance, P., Choquet, C., Cloppet-Fontaine, A., Colosi, L., Couset, B., Crestani, B., Crocket, F., Debit, A., Delanoe, K, Descamps, V., Dieude, P., Dossier, A., Douron, N., Dupeyrat, E., Emeyrat, N., Fernet, C., Goulenok, T., Harent, S., Jouenne, R., Justet, A., Leleu, A., Lerat, I., Lilamand, M., Mal, H., Marceau, A., Metivier, A.-C., Oplelatora, K., Papo, T., Pelletier, A.-L., Pereira, L., Pradere, P., Prommier, R, Ralainnazava, P., Ranaivoision, M., Raynaud-Simon, A., Rioux, C., Sacre, K., Verry, V., Vuong, V., Yazdapanah, Y., Houhou, N., Géraud, P., Driss, V., Maugueret, V., Crantelle, L., Agostini, C., Ray, M., Letois, F., Mura, T., Serrand, C., Noslier, S., Giordano, A., Chevassus, H., Nyiramigisha, E., Merle, C., Bourdin, A., Konaté, A., Capdevilla, X., Du Cailar, G., Terminet, A., Blain, H., Leglise, M., Le Quellec, A., Corne, P., Landreau, L., Klouche, K., Bourgeois, A., Sebbane, M., Mourad, G., Leray, H., Postil, D., Alcolea, S., Couve-Deacon, E., Rogez, S., Argaud, L., Cour, M., Hernu, R., Simon, M., Baudry, T., Tazarourte, K., Bui-Xuan, C., Fattoum, J., Valette, M., Rochas, S., Cochennec, S., Thébault, E., Revest, M., Sébillotte, M., Le Bot, A., Baldeyrou, M., Patrat-Delon, S., Cailleaux, M., Pronier, C., CHU Pontchaillou [Rennes], ARN régulateurs bactériens et médecine (BRM), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Virulence Bactérienne et Infections Chroniques (VBIC), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), F-CRIN, Innovative clinical research network in vaccinology (I-REIVAC), Hospices Civils de Lyon (HCL), Centre International de Recherche en Infectiologie (CIRI), École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), CIC - CHU Bichat, Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), AP-HP - Hôpital Bichat - Claude Bernard [Paris], Centre d'Investigation Clinique de Limoges (CIC1435), CHU Limoges-Institut National de la Santé et de la Recherche Médicale (INSERM), Anti-infectieux : supports moléculaires des résistances et innovations thérapeutiques (RESINFIT), CHU Limoges-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST), Université de Limoges (UNILIM)-Université de Limoges (UNILIM), CIC Montpellier, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Saint Eloi (CHRU Montpellier), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Montpellier, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), CIC Cochin Pasteur (CIC 1417), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôtel-Dieu-Groupe hospitalier Broca-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] (PhyMedExp), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM), and This work was not funded. The study sites received funding from Sanofi Pasteur and MSD for the FLUVAC study. Vaccine producers had no role in the study design, data analysis, decision to publish or preparation of the manuscript.

Subjects
Adult, Multidisciplinary, [SDV]Life Sciences [q-bio], Respiratory Syncytial Virus Infections, [SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Adrenal Cortex Hormones, Virus Diseases, Respiratory Syncytial Virus, Human, Influenza, Human, Viruses, Humans, Prospective Studies, Respiratory Tract Infections
Abstract

Inhaled corticosteroids (ICS) have been associated with increased risk of pneumonia. Their impact on respiratory virus infections is unclear. We performed a post-hoc analysis of the FLUVAC cohort, a multicenter prospective cohort study of adults hospitalized with influenza-like illness (ILI) during six consecutive influenza seasons (2012–2018). All patients were tested for respiratory virus infection by multiplex PCR on nasopharyngeal swabs and/or bronchoalveolar lavage. Risk factors were identified by logistic regression analysis. Among the 2658 patients included, 537 (20.2%) were treated with ICS before admission, of whom 282 (52.5%, 282/537) tested positive for at least one respiratory virus. Patients on ICS were more likely to test positive for non-influenza respiratory viruses (25.1% vs. 19.5%, P = 0.004), especially for adenovirus (aOR 2.36, 95% CI 1.18–4.58), and respiratory syncytial virus (aOR 2.08, 95% CI 1.39–3.09). Complications were reported in 55.9% of patients on ICS (300/537), primarily pneumonia (171/535, 32%). Among patients on chronic ICS who tested positive for respiratory virus, 14.2% (40/282) were admitted to intensive care unit, and in-hospital mortality rate was 2.8% (8/282). Chronic use of ICS is associated with an increased risk of adenovirus or RSV infections in patients admitted for ILI.

Published
2021
Full Text
View/download PDF

2. Moderate influenza vaccine effectiveness against hospitalisation with A(H3N2) and A(H1N1) influenza in 2013–14: Results from the InNHOVE network

Author

Rondy, M., Castilla, J., Launay, O., Costanzo, S., Ezpeleta, C., Galtier, F., de Gaetano Donati, K., Moren, A., Beristain, X., Chamorro, J., Gabari, M., Artajo, P., Lameiro, F., Barrado, L., Ortega, M., Torres, M., Garcia Irure, J. J., Irisarri, F., Garcia Cenoz, M., Guevara, M., Casado, I., Diaz, J., Martinez-Baz, I., Lenzi, N., Lesieur, Z., Bonmarin, I., Merle, C., Foulongne, V., Letois, F., Driss, V., Geraud, P., Bourdin, A., Landreau, L., Konate, A., Corne, P., Sebbane, M., Klouche, K., Leglise, M. -S., Loulergue, P., Kanaan, R., Dumas, F., Krivine, A., Moncilovic, S., Ali, N., Duval, X., Costa, Y., Ait Naman, R., Yazdapanah, Y., Caseris, M., Dournon, N., Papo, T., Dossier, A., Becheur, H., Pelletier, A. -L., Mal, M., Marceau, A., Aubier, M., Bories, R., Casalino, E., Choquet, C., Houhou, N., Vanhems, P., Regis, C., Jouneau, S., Laine, F., Tattevin, P., Beuzit, L., Thebault, E., Fey, S., Lagathu et Sophie Cha, G., Postil, D., Alcolea, S., Rogez, S., Valette, M., Lina, B., Cauda, R., Taccari, F., Santangelo, R., Perlasca, F., Fichera, G., Dara, M., Iacoviello, L., Olivieri, M., CIC - Biotherapie - AP-HP (cochin - Pasteur), Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Saint-Eloi, CIC Montpellier, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-CHU Saint-Eloi-Institut National de la Santé et de la Recherche Médicale (INSERM), Biocommunication en Cardio-Métabolique (BC2M), Université de Montpellier (UM), Hôpital Saint Eloi (CHRU Montpellier), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Saint Eloi (CHRU Montpellier), and Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
Male, [SDV]Life Sciences [q-bio], Logistic regression, medicine.disease_cause, Influenza A Virus, H1N1 Subtype, 0302 clinical medicine, Outcome Assessment, Health Care, Influenza A virus, Immunology and Allergy, Medicine, 030212 general & internal medicine, hospital, Young adult, media_common, Aged, 80 and over, Influenza vaccine, Vaccination, virus diseases, Middle Aged, Research Papers, 3. Good health, Hospitalization, case control studies, Italy, Influenza Vaccines, Female, France, Seasons, Adult, medicine.medical_specialty, Adolescent, 030231 tropical medicine, Immunology, Young Adult, 03 medical and health sciences, Internal medicine, Influenza, Human, A h1n1 influenza, Humans, media_common.cataloged_instance, European Union, European union, Intensive care medicine, Aged, Pharmacology, business.industry, Influenza A Virus, H3N2 Subtype, Case-control study, Influenza, multicentre studies, Logistic Models, Spain, Case-Control Studies, business, Sentinel Surveillance
Abstract

International audience; We conducted a multicentre test negative case control study to estimate the 2013–14 influenza vaccine effectiveness (IVE) against hospitalised laboratory confirmed influenza in 12 hospitals in France, Italy and Spain. We included all ≥18 years hospitalised patients targeted by local influenza vaccination campaign reporting an influenza-like illness within 7 days before admission. We defined as cases patients RT-PCR positive for influenza and as controls those negative for all influenza virus. We used a logistic regression to calculate IVE adjusted for country, month of onset, chronic diseases and age. We included 104 A(H1N1)pdm09, 157 A(H3N2) cases and 585 controls. The adjusted IVE was 42.8% (95%CI: 6.3;65;0) against A(H1N1)pdm09. It was respectively 61.4% (95%CI: −1.9;85.4), 39.4% (95%CI: −32.2;72.2) and 19.7% (95%CI:-148.1;74.0) among patients aged 18–64, 65–79 and ≥80 years. The adjusted IVE against A(H3N2) was 38.1% (95%CI: 8.3;58.2) overall. It was respectively 7.8% (95%CI: −145.3;65.4), 25.6% (95%CI: −36.0;59.2) and 55.2% (95%CI: 15.4;76.3) among patients aged 18–64, 65–79 and ≥80 years. These results suggest a moderate and age varying effectiveness of the 2013–14 influenza vaccine to prevent hospitalised laboratory-confirmed influenza. While vaccination remains the most effective prevention measure, developing more immunogenic influenza vaccines is needed to prevent severe outcomes among target groups. © 2016 Taylor & Francis.

Published
2016
Full Text
View/download PDF

3. Gaspillage alimentaire en restauration d’entreprise : une analyse qualitative des normes personnelles et sociales

Author

Sebbane, M. and Costa, S.

Subjects
FOOD WASTE, MASS CATERING, PERSONAL AND SOCIAL NORMS, GASPILLAGE ALIMENTAIRE, NORMES PERSONNELLES ET SOCIALES, RESTAURATION COLLECTIVE, food waste,consumer,gaspillage alimentaire,mass catering,personal and social norm, jel:D12, jel:A13
Abstract

With the adoption of the national pact against waste, France's goal is to halve the phenomenon by 2025. In this article, we present the results of an exploratory study about the existence and influence of personal and social norms on waste behavior in corporate catering. We show the existence of a personal norm against waste and contradictory descriptive and injunctive norms that are expressed either at the level of the group we are eating with or that of the entirety of customers., Avec l’adoption du pacte national de lutte contre le gaspillage alimentaire, la France se fixe comme objectif de réduire de moitié le phénomène d’ici 2025. Dans cet article nous présentons les résultats d’une étude exploratoire sur la présence et l’influence des normes personnelles et sociales sur les comportements de gaspillage dans des restaurants collectifs d’entreprises. Nous montrons l’existence d’une norme personnelle de non gaspillage ainsi que la perception de normes descriptives et injonctives contradictoires qui peuvent être activées à deux niveaux de proximité : au niveau du groupe avec lequel on mange ou à l’échelle de l’ensemble des usagers du restaurant.

Published
2015

4. 2012/13 influenza vaccine effectiveness against hospitalised influenza A(H1N1)pdm09, A(H3N2) and B: estimates from a European network of hospitals

Author

Rondy, M., Launay, O., Puig-Barberà, J., Gefenaite, G., Castilla, J., Gaetano Donati, K., Galtier, F., Hak, E., Guevara, M., Costanzo, S., Moren, A., Lenzi, N., Lesieur, Z., Bonmarin, I., Duval, X., Costa, Y., Kanagaratnam, A., Yazdapanah, Y., Caseris, M., Dournon, N., Papo, T., Dossier, A., Bécheur, H., Pelletier, A. -L, Mal, H., Marceau, A., Aubier, M., Bories, R., Casalino, E., Choquet, C., Houhou, N., Loulergue, P., Kanaan, R., Dumas, F., Postil, D., Alcoléa, S., Rogez, S., Vanhaems, P., Régis, C., Merle, C., Foulongne, V., Ray, M., Maugueret-Doublet, V., Bourdin, A., Landreau, L., Konaté, A., Corne, P., Sebbane, M., Klouche, K., Léglise, M. -S, Valette, M., Lina, B., Carrat, F., Chau, F., Díez-Domingo, J., Escribano-López, B., Arnedo-Pena, A., Ruiz-García, M., Tortajada-Girbés, M., Munuera, C. C., Sañudo, J. B., Larrea-González, R., Gil-Guillén, V., Schwarz-Chavarri, G., Rahamat-Langendoen, J., Hubert Niesters, Ambrozaitis, A., Jancoriene, L., Mickiene, A., Kuliese, M., Velyvyte, D., Stolk, R. P., Zagminas, K., Ezpeleta, C., Chamorro, J., Artajo, P., Lameiro, F., Navascués, A., Ortega, M., Torres, M., Irure, J. J. G., Irisarri, F., Cenoz, M. G., Martínez-Baz, I., Cauda, R., Donato, C., Santangelo, R., Perlasca, F., Fichera, G., Dara, M., Iacoviello, L., Olivieri, M., EpiConcept [Paris], REseau national d'Investigation clinique en VACcinologie (REIVAC), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôtel-Dieu-Groupe hospitalier Broca-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de Gestion des Essais de Produits de Santé (CeNGEPS), CIC Cochin Pasteur (CIC 1417), Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupe hospitalier Broca-Université Paris Descartes - Paris 5 (UPD5)-Hôtel-Dieu-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), CIC Montpellier, Institut National de la Santé et de la Recherche Médicale (INSERM), Biocommunication en Cardio-Métabolique (BC2M), Université de Montpellier (UM), Centre National de Gestion des Essais de Produits de Santé (CeNGEPS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupe hospitalier Broca-Hôtel-Dieu-CHU Cochin [AP-HP]-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Cochin [AP-HP]-Hôtel-Dieu-Université Paris Descartes - Paris 5 (UPD5)-Groupe hospitalier Broca-Institut National de la Santé et de la Recherche Médicale (INSERM), Microbes in Health and Disease (MHD), Real World Studies in PharmacoEpidemiology, -Genetics, -Economics and -Therapy (PEGET), and Centre National de Gestion des Essais de Produits de Santé (CeNGEPS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupe hospitalier Broca-Hôtel-Dieu-Hôpital Cochin [AP-HP]

Subjects
Male, Pediatrics, Epidemiology, TEST-NEGATIVE DESIGN, medicine.disease_cause, Logistic regression, Influenza A Virus, H1N1 Subtype, 80 and over, Influenza A Virus, Influenza A virus, Medicine, PROTECTION, media_common, Aged, 80 and over, Incidence (epidemiology), Vaccination, virus diseases, Middle Aged, 3. Good health, Europe, Hospitalization, Treatment Outcome, Influenza Vaccines, H3N2 Subtype, Female, Seasons, Human, Adult, medicine.medical_specialty, Adolescent, Influenza vaccine, Settore MED/07 - MICROBIOLOGIA E MICROBIOLOGIA CLINICA, Virus, Young Adult, Virology, Influenza, Human, Humans, media_common.cataloged_instance, H1N1 Subtype, European Union, European union, Aged, business.industry, Influenza A Virus, H3N2 Subtype, Public Health, Environmental and Occupational Health, Case-control study, Influenza, Confidence interval, Influenza B virus, Logistic Models, ANTIBODY, Case-Control Studies, CHALLENGE, business, Sentinel Surveillance, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

International audience; While influenza vaccines aim to decrease the incidence of severe influenza among high-risk groups, evidence of influenza vaccine effectiveness (IVE) among the influenza vaccine target population is sparse. We conducted a multicentre test-negative case-control study to estimate IVE against hospitalised laboratory-confirmed influenza in the target population in 18 hospitals in France, Italy, Lithuania and the Navarre and Valencia regions in Spain. All hospitalised patients aged ≥18 years, belonging to the target population presenting with influenza-like illness symptom onset within seven days were swabbed. Patients positive by reverse transcription polymerase chain reaction for influenza virus were cases and those negative were controls. Using logistic regression, we calculated IVE for each influenza virus subtype and adjusted it for month of symptom onset, study site, age and chronic conditions. Of the 1,972 patients included, 116 were positive for influenza A(H1N1)pdm09, 58 for A(H3N2) and 232 for influenza B. Adjusted IVE was 21.3% (95% confidence interval (CI): -25.2 to 50.6; n=1,628), 61.8% (95% CI: 26.8 to 80.0; n=557) and 43.1% (95% CI: 21.2 to 58.9; n=1,526) against influenza A(H1N1) pdm09, A(H3N2) and B respectively. Our results suggest that the 2012/13 IVE was moderate against influenza A(H3N2) and B and low against influenza A(H1N1) pdm09.

Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results